Results 51 to 60 of about 20,878 (216)

Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias

Frontiers in Pharmacology
The Bruton’s Tyrosine Kinase Inhibitor, ibrutinib, has been widely employed due to its significant efficacy in B-cell lymphoma. However, the subsequent cardiac complications, notably atrial fibrillation (AF) and ventricular arrhythmias (VAs),associated ...
Yilin Pan, Yilin Pan, Yanan Zhao, Hangyu Ren, Hangyu Ren, Xintong Wang, Caixia Liu, Beibei Du, Kumaraswamy Nanthakumar, Ping Yang   +9 more
doaj   +1 more source

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Blood Cancer Journal, 2021
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain.
Natalia Timofeeva, Varsha Gandhi
doaj   +1 more source

Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study [PDF]

, 2023
John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien   +13 more
openalex   +1 more source

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia

Case Reports in Hematology, 2021
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL).
Sara Kristina Viberg Tjønnfjord, Eirik Brekka Tjønnfjord, Zbigniew Konopski, Geir Erland Tjønnfjord   +3 more
doaj   +1 more source

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Journal of Hematology & Oncology, 2021
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL).
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam   +14 more
doaj   +1 more source

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

British Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian, Chiara Arrigoni, Francesco Bertoni, Matteo Moretti   +12 more
wiley   +1 more source

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Journal of Hematology & Oncology, 2021
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib,
Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, Erin Hertlein   +13 more
doaj   +1 more source

A novel MDM2-p53 antagonist APG115 exerts synergistic effect with ibrutinib via targeting MCL-1 in chronic lymphocytic leukemia [PDF]

, 2022
Yang Han, Xinting Hu, Hua Wang, Tian Zheng, Xin Zhang, Shunfeng Hu, Ya Zhang, Xin Wang   +7 more
openalex   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways

Frontiers in Medicine
IntroductionIbrutinib, widely used in leukemia treatment, has been implicated in sensorineural hearing loss; however, its underlying mechanisms remain unclear.MethodsThis study investigated the impact of ibrutinib on hearing using HEI-OC1 cells, cochlear
Yuhua Zhang, Yun Xiao, Yongjun Zhu, Lin Yan, Nan Cheng, Yongjie Wei, Yanling Zhang, Yanghua Tian, Wei Cao, Jianming Yang   +9 more
doaj   +1 more source